Broad Spectrum Efficacy
The most common antibiotics available today are generally only effective against certain classes of bacteria. Penicillin, for example, is primarily effective against Gram-positive organisms. More recently, broad-spectrum antibiotics like ampicillin have been developed, which can treat a wider range of infections. Unfortunately, these more powerful, broad-spectrum antibiotics pose specific risks, particularly the disruption of native, normal bacterial flora (e.g., gut microbiota) and the development of antimicrobial resistance.
As a result, the development of locally delivered (to avoid systemic disruption) broad-spectrum compounds that do not increase the risk of antimicrobial resistance is highly warranted.
Vast’s proprietary nitric oxide-releasing compounds are broad-spectrum, local acting, and not prone to resistance, thus far exceeding what is possible today with traditional antibiotics (Table 1). Our compounds have demonstrated high in vitro activity and high potency against a wider range of infectious bacteria than any existing antibiotic. Recently, we announced the ability to inhibit viral replication of SARS-CoV-2, the human coronavirus that causes COVID-19.